SHMT2 and neoplasm: There are already preclinical studies exploring and evaluating the potential efficacy of inhibitors targeting SHMT2 and cytosolic C1 enzymes 59-61, among which AGF347 showed a satisfying and compelling anti-tumour effects in vivo in both early-stage and advanced stage MIA PaCa-2 pancreatic tumour xenografts62.